Associated Genetic Biomarkers
NOTCH4 is altered in 2.30% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in NOTCH4 are NOTCH4 Mutation (1.59%), NOTCH4 Amplification (0.05%), NOTCH4 G1891Afs*13 (0.02%), NOTCH4 Loss (0.02%), and NOTCH4 E1836K (0.01%) .
NOTCH4 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain NOTCH4 status as an inclusion criterion, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).
Trials with NOTCH4 status in the inclusion eligibility criteria most commonly target adenoid cystic carcinoma, breast carcinoma, cholangiocarcinoma, and colon carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is NOTCH4 Mutation .
Al101, ly3039478, abemaciclib, carboplatin, and cisplatin are the most frequent therapies in trials with NOTCH4 as an inclusion criteria .
Significance of NOTCH4 in Diseases
Colon Carcinoma +
Malignant Solid Tumor +
Breast Carcinoma +
Adenoid Cystic Carcinoma +
NOTCH4 is an inclusion criterion in 1 clinical trial for adenoid cystic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NOTCH4 status and adenoid cystic carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
NOTCH4 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) .
NOTCH4 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH4 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) .
Soft Tissue Sarcoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.